The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.

The present invention relates to a consumable product comprising malted oats and/or a leachate of malted oats for use, if consumed in an amount sufficient enough to induce endogenous production of Protein Antisecretory Factor (Protein AF) and/or fragments thereof in a mammal after consumption, in increasing cardiac output and/or decreasing the recovery process of a mammal during and/or after physical activity, thereby treating and/or preventing muscle damage caused by strains and/or tears in an athletic mammal, as well as for preventing paralysis during and/or after physical activity. Said consumption of said consumable product before during and/or after said physical activity has for the first time been found to stabilize the Erythrocyte Fluid Volume fraction (EFV) of a mammal during and/or after physical activity at a value of no more than 3% over resting value, such as at a value between 37-38%, and to stabilize the creatine kinase value of said mammal at a lower value than for mammals not consuming SPC, i.e. at values which indicate reduced muscle stress and damage.

The use of the consumable product is intended as food or feed for humans and/or animals, such as but not limited to horses and dogs.

The present invention relates to a consumable product comprising malted oats and/or a leachate of malted oats for use, if consumed in an amount sufficient enough to induce endogenous production of Protein Antisecretory Factor (Protein AF) and/or fragments thereof in a mammal after consumption, in increasing cardiac output and/or decreasing the recovery process of a mammal during and/or after physical activity, thereby treating and/or preventing muscle damage caused by strains and/or tears in an athletic mammal, as well as for preventing paralysis during and/or after physical activity. Said consumption of said consumable product before during and/or after said physical activity has for the first time been found to stabilize the Erythrocyte Fluid Volume fraction (EFV) of a mammal during and/or after physical activity at a value of no more than 3% over resting value, such as at a value between 37-38%, and to stabilize the creatine kinase value of said mammal at a lower value than for mammals not consuming SPC, i.e. at values which indicate reduced muscle stress and damage.

The use of the consumable product is intended as food or feed for humans and/or animals, such as but not limited to horses and dogs.

Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or integrins. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, inflammatory bowel syndrome, non-alcoholic fatty liver disease, and nonalcoholic steatohepatitis.

Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or integrins. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, inflammatory bowel syndrome, non-alcoholic fatty liver disease, and nonalcoholic steatohepatitis.

Provided herein are compositions and methods for treating or preventing a neurodegenerative disease, a neurodevelop-mental disease, a myodegenerative disease, a prion disease, a lysosomal storage disease or cancer in a subject.

Provided herein are compositions and methods for treating or preventing a neurodegenerative disease, a neurodevelop-mental disease, a myodegenerative disease, a prion disease, a lysosomal storage disease or cancer in a subject.

The current invention is based on the determination that a S1P receptor modulator compound of formula (I):

##STR00001##

decreases the heart rate of a subject to which it is administered by about 5 beats/min or less daily, or about 4 beats/min or less daily, or about 3 beats/min or less daily, or about 2 beats/min or less daily, wherein the S1P receptor modulator is administered at an initial daily dosage which is substantially the same as the standard daily therapeutic dosage.

The current invention is based on the determination that a S1P receptor modulator compound of formula (I):

##STR00001##

decreases the heart rate of a subject to which it is administered by about 5 beats/min or less daily, or about 4 beats/min or less daily, or about 3 beats/min or less daily, or about 2 beats/min or less daily, wherein the S1P receptor modulator is administered at an initial daily dosage which is substantially the same as the standard daily therapeutic dosage.

The invention relates to electrically-heatable plasters which comprise a self-adhesive skin contact layer, an electrically-conductive textile fabric in which electrically-conductive fibres are in contact with one another, as a heating element, and optionally at least one active substance, as well as to a method for production and the use of same for local heat therapy and/or transdermal application of active substances.